Latest Healthcare Market News

Resonance Health has reported record half-year revenue and strong progress in clinical trials, alongside promising new technology deployments set to enhance its global footprint.

Adheris Health reported a sharp decline in Q2 FY26 revenue but is pushing ahead with leadership changes, cost cuts, and a new digital platform to reshape its future.

OncoSil Medical has reported a record quarter for dose sales alongside key European market entries and a successful manufacturing milestone, signalling growing momentum for its pancreatic cancer treatment.

PainChek has achieved FDA regulatory clearance enabling its device to qualify for US Remote Therapeutic Monitoring reimbursement, positioning the company for significant growth in the expanding US healthcare market. The company also reports strong global licence growth and a solid pipeline across multiple regions.

PainChek has secured FDA De Novo clearance, enabling entry into the vast US healthcare market with a $3 billion Remote Therapeutic Monitoring opportunity. The company reports $5.6 million contracted ARR and a strong global footprint in aged care.

Nexsen Limited has reported significant progress in its rapid diagnostic technologies, including a key FDA pre-submission for its GBS rapid sensor and a solid cash reserve post-IPO to support commercialisation efforts.

Epiminder Limited has successfully listed on the ASX, raising $125 million to commercialise its FDA-approved Minder device. The company has initiated the first US implant and secured five leading medical centres for its DETECT study.

Cyclopharm’s Technegas has been recognised as the preferred ventilation agent in a pivotal draft US lung imaging guideline, signalling a major boost for its adoption in American clinical practice.

Echo IQ has completed clinical validation of its EchoSolv HF heart failure detection software with the Mayo Clinic Platform, achieving outstanding accuracy. The company has now formally submitted its FDA 510(k) clearance application, positioning itself for significant commercial expansion in the US healthcare market.

Rhythm Biosciences has begun commercialising its blood-based colorectal cancer test, ColoSTAT®, following key accreditations and validation. The company also secured a strategic partnership with NHS England and expanded its geneType™ platform globally.

Osteopore Limited has inked a three-year exclusive distribution agreement with MontsMed to introduce its advanced orthopaedic trauma reconstruction products into Hong Kong, positioning itself strategically within the Greater Bay Area.

Vitasora Health has completed an A$11 million capital raise, including a cornerstone investment, bolstering its balance sheet to support ambitious growth in the US healthcare market. The company targets cash flow breakeven by the end of FY2026 amid expanding patient programs and new partnerships.